Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:BCAB NASDAQ:HLVX NASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.85+5.7%$1.87$1.33▼$3.58$87.15M0.7464,124 shs7,955 shsBCABBioAtla$0.36+2.0%$0.41$0.24▼$2.53$20.86M0.91905,238 shs99,961 shsHLVXHilleVax$2.04-1.2%$1.96$1.34▼$2.17$102.64M0.76245,448 shs2,280 shsMISTMilestone Pharmaceuticals$1.58-0.3%$1.68$0.63▼$2.75$84.20M0.961.13 million shs150,504 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%-8.38%-7.89%+12.90%-30.28%BCABBioAtla0.00%-8.21%-12.31%+3.87%-79.29%HLVXHilleVax0.00%-1.44%+10.75%+24.10%+16.38%MISTMilestone Pharmaceuticals0.00%+1.28%-6.51%+56.44%+6.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAGAdagene2.304 of 5 stars3.35.00.00.00.91.70.0BCABBioAtla1.6282 of 5 stars3.31.00.00.00.62.50.6HLVXHilleVax1.7107 of 5 stars1.05.00.00.00.03.31.3MISTMilestone Pharmaceuticals2.8429 of 5 stars3.24.00.00.02.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 2.50Moderate Buy$8.00332.43% UpsideBCABBioAtla 2.50Moderate Buy$5.001,292.76% UpsideHLVXHilleVax 2.00Hold$2.00-1.72% DownsideMISTMilestone Pharmaceuticals 2.40Hold$7.00344.44% UpsideCurrent Analyst Ratings BreakdownLatest BCAB, HLVX, MIST, and ADAG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K871.54N/AN/A$1.14 per share1.62BCABBioAtla$11M1.91N/AN/A$0.25 per share1.44HLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/AMISTMilestone Pharmaceuticals$1M84.20N/AN/A$0.25 per share6.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)BCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)HLVXHilleVax-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)MISTMilestone Pharmaceuticals-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)Latest BCAB, HLVX, MIST, and ADAG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BCABBioAtla-$0.29N/AN/AN/AN/AN/A8/14/2025Q2 2025HLVXHilleVax-$0.14N/AN/AN/AN/AN/A8/14/2025Q2 2025MISTMilestone Pharmaceuticals-$0.18N/AN/AN/AN/AN/A5/14/2025Q1 2025MISTMilestone Pharmaceuticals-$0.19-$0.31-$0.12-$0.31N/AN/A5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/A5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/ABCABBioAtlaN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.012.302.30BCABBioAtlaN/A2.352.35HLVXHilleVaxN/A25.3225.32MISTMilestone Pharmaceuticals4.064.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%BCABBioAtla77.23%HLVXHilleVax86.42%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%BCABBioAtla11.50%HLVXHilleVax24.90%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.11 million37.12 millionNot OptionableBCABBioAtla6058.42 million51.70 millionOptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableMISTMilestone Pharmaceuticals3053.46 million43.04 millionOptionableBCAB, HLVX, MIST, and ADAG HeadlinesRecent News About These CompaniesResearch Analysts Set Expectations for MIST Q3 EarningsJuly 19 at 2:41 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)July 18 at 8:07 PM | theglobeandmail.comMilestone Pharmaceuticals Remains A Buying Opportunity Despite Recent DilutionJuly 18 at 3:06 PM | seekingalpha.comEquities Analysts Set Expectations for MIST Q3 EarningsJuly 17, 2025 | marketbeat.comResearch Analysts Issue Forecasts for MIST FY2028 EarningsJuly 17, 2025 | americanbankingnews.comMilestone Pharmaceuticals Announces Public Offering for $48.7MJuly 16, 2025 | theglobeandmail.comTD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)July 16, 2025 | theglobeandmail.comHC Wainwright Issues Pessimistic Estimate for MIST EarningsJuly 16, 2025 | marketbeat.comUS FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal sprayJuly 14, 2025 | pharmabiz.comPMilestone Pharmaceuticals Inc. (MIST) Stock Price Today - WSJJuly 11, 2025 | wsj.comMilestone says heart disorder therapy under FDA review againJuly 11, 2025 | msn.comMilestone Pharmaceuticals stock plunges on public offering announcementJuly 11, 2025 | au.investing.comMilestone Pharmaceuticals Shares Drop Sharply After Public Offering AnnouncementJuly 11, 2025 | msn.comWhy Is Milestone Pharmaceuticals Stock Plunging On Friday?July 11, 2025 | benzinga.comCrude Oil Rises Sharply; Milestone Pharmaceuticals Shares PlungeJuly 11, 2025 | benzinga.comMilestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common WarrantsJuly 11, 2025 | globenewswire.comMilestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal SprayJuly 11, 2025 | finance.yahoo.comMilestone Pharmaceuticals proposes capital raise via securities offeringJuly 11, 2025 | msn.comMilestone Pharmaceuticals Announces Proposed Public OfferingJuly 11, 2025 | globenewswire.comMilestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal SprayJuly 11, 2025 | globenewswire.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from AnalystsJuly 11, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAB, HLVX, MIST, and ADAG Company DescriptionsAdagene NASDAQ:ADAG$1.85 +0.10 (+5.71%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.BioAtla NASDAQ:BCAB$0.36 +0.01 (+1.99%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.HilleVax NASDAQ:HLVX$2.04 -0.03 (-1.21%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Milestone Pharmaceuticals NASDAQ:MIST$1.58 -0.01 (-0.32%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
